GFR-话题@MedSci

#GFR#

483篇内容 | 2494人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534560, encodeId=dac31534560fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果, objectType=article, longId=215256, objectId=71942152560f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71942152560f, replyNumber=0, likeNumber=69, createdTime=2021-08-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71942152560f, moduleTitle=J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71942152560f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534559, encodeId=7fc915345595a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, objectType=article, longId=214990, objectId=95022149908f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95022149908f, replyNumber=0, likeNumber=73, createdTime=2021-07-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95022149908f, moduleTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95022149908f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534558, encodeId=b40215345588a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, objectType=article, longId=214456, objectId=4803214456af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4803214456af, replyNumber=0, likeNumber=101, createdTime=2021-07-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4803214456af, moduleTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4803214456af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534557, encodeId=65bb153455e27, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, objectType=article, longId=214414, objectId=2f7c2144147c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7c2144147c, replyNumber=0, likeNumber=94, createdTime=2021-07-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7c2144147c, moduleTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7c2144147c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534556, encodeId=effe1534556b2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=64, createdTime=2021-07-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534555, encodeId=1ff5153455515, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Br J Cancer：抗EGFR疗法治疗结直肠癌的亚型特异性疗效取决于化疗药物选择, objectType=article, longId=214205, objectId=f8bf2142050d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8bf2142050d, replyNumber=0, likeNumber=72, createdTime=2021-07-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8bf2142050d, moduleTitle=Br J Cancer：抗EGFR疗法治疗结直肠癌的亚型特异性疗效取决于化疗药物选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8bf2142050d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534554, encodeId=652f153455430, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Br J Cancer：抗EGFR治疗中低位直肠癌与左侧结肠癌患者的疗效不同, objectType=article, longId=213633, objectId=908421363343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=908421363343, replyNumber=0, likeNumber=76, createdTime=2021-07-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=908421363343, moduleTitle=Br J Cancer：抗EGFR治疗中低位直肠癌与左侧结肠癌患者的疗效不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=908421363343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534553, encodeId=efdf153455315, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=67, createdTime=2021-07-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534552, encodeId=2899153455285, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌, objectType=article, longId=213319, objectId=eb9e21331927, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb9e21331927, replyNumber=0, likeNumber=0, createdTime=2021-06-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb9e21331927, moduleTitle=JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb9e21331927)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534551, encodeId=e3ce153455193, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, objectType=article, longId=213145, objectId=141f2131458b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141f2131458b, replyNumber=0, likeNumber=84, createdTime=2021-06-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141f2131458b, moduleTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141f2131458b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534550, encodeId=79f0153455064, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, objectType=article, longId=212480, objectId=b2a22124805f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2a22124805f, replyNumber=0, likeNumber=139, createdTime=2021-06-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2a22124805f, moduleTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2a22124805f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534549, encodeId=f5b7153454968, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用, objectType=article, longId=212378, objectId=98962123e86a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98962123e86a, replyNumber=0, likeNumber=69, createdTime=2021-06-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98962123e86a, moduleTitle=Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98962123e86a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534547, encodeId=2d37153454e5e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, objectType=article, longId=211907, objectId=ac0e21190e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0e21190e76, replyNumber=0, likeNumber=80, createdTime=2021-05-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0e21190e76, moduleTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0e21190e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534548, encodeId=0be5153454881, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益, objectType=article, longId=211619, objectId=39722116191a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39722116191a, replyNumber=0, likeNumber=74, createdTime=2021-05-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39722116191a, moduleTitle=武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39722116191a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534546, encodeId=8fb115345468b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群, objectType=article, longId=211422, objectId=34082114222e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34082114222e, replyNumber=0, likeNumber=74, createdTime=2021-05-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34082114222e, moduleTitle=Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34082114222e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534545, encodeId=09bc153454582, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, objectType=article, longId=211341, objectId=0e6621134127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e6621134127, replyNumber=0, likeNumber=66, createdTime=2021-05-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e6621134127, moduleTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e6621134127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534544, encodeId=436d15345443b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态, objectType=article, longId=210910, objectId=93ee2109107f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ee2109107f, replyNumber=0, likeNumber=76, createdTime=2021-05-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ee2109107f, moduleTitle=Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ee2109107f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534543, encodeId=0502153454378, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批, objectType=article, longId=210637, objectId=db3b21063ea2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db3b21063ea2, replyNumber=0, likeNumber=0, createdTime=2021-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db3b21063ea2, moduleTitle=武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db3b21063ea2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534542, encodeId=d32815345428f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, objectType=article, longId=209220, objectId=b2172092201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2172092201a, replyNumber=0, likeNumber=66, createdTime=2021-04-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2172092201a, moduleTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2172092201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534541, encodeId=7885153454128, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响, objectType=article, longId=209060, objectId=19bd20906089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19bd20906089, replyNumber=0, likeNumber=0, createdTime=2021-03-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19bd20906089, moduleTitle=Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19bd20906089)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol: Amivantamab治疗铂类进展的EGFR 20外显子插入突变非小细胞肺癌的安全性和疗效：I期研究CHRYSALIS的初次分析结果

2021-08-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究

2021-07-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

2021-07-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

2021-07-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2021-07-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Br J Cancer：抗EGFR疗法治疗结直肠癌的亚型特异性疗效取决于化疗药物选择

2021-07-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Br J Cancer：抗EGFR治疗中低位直肠癌与左侧结肠癌患者的疗效不同

2021-07-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2021-07-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌

2021-06-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L

2021-06-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应

2021-06-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Br J Cancer：安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用

2021-06-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果

2021-05-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益

2021-05-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群

2021-05-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用

2021-05-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态

2021-05-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

武田宣布美国FDA将优先审理Mobocertinib (TAK-788)治疗EGFR外显子20插入+转移性非小细胞肺癌的新药报批

2021-05-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！

2021-04-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响

2021-03-28

科室
- - 订阅+
  - 更多科室
工具
服务